49. Systemic lupus erythematosus Clinical trials / Disease details

Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01773616 (ClinicalTrials.gov)	April 2015	1/11/2012	Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis	Phase 3 Open Label Randomised Multicentre Controlled Trial of Rituxmab and Mycophenolate Mofetil Without Oral Steroids for the Treatment of Lupus Nephritis	Systemic Lupus Erythematosus, Lupus Nephritis	Drug: Oral prednisolone;Drug: Rituximab;Drug: Mycophenolate mofetil;Drug: Methyl prednisolone	Imperial College London	Karolinska Institutet;Ohio State University;Dutch Working Party on Systemic Lupus Erythematosus;EULAR Lupus Nephritis Trial Network Study Group	Terminated	12 Years	75 Years	All	24	Phase 3	United Kingdom
2	JPRN-UMIN000000639	2007/03/01	16/03/2007	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III study of Rituximab in Patients with Systemic Lupus Erythematosus	A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II/III study of Rituximab in Patients with Systemic Lupus Erythematosus - Rituximab clinical Investigation in Systemic lupus Erythematosus (RISE study)	Systemic lupus erythematosus	IDEC-C2B8 plus oral prednisolone(tapering) 1000 mg of IDEC-C2B8 on days 1 and 15.Repeated at an interval of 6 months (Days 169 and 183). Placebo plus oral prednisolone(tapering) 1000 mg of placebo day 1 and 15.Repeated at an interval of 6 months (Days 169 and 183).	Zenyaku Kogyo Co., Ltd.	NULL	Complete: follow-up complete	16years-old	75years-old	Male and Female	150	Phase 2/3	Japan